Observational studyCritical care (London, England)2026
Neuroprognostication after cardiac arrest in patients without withdrawal of life-sustaining therapy: a prospective observational multicenter study.
Observational study in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02231060 (Hypoxia and Outcome Prediction in Early Stage Coma), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors
Who cites it
1 citing paper in PubMed.
- Neuroprognostication after cardiac arrest: time-anchored reassessment and uncertainty around zero false positives.Critical care (London, England) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroprognostication after cardiac arrest (CA) is critical for guiding treatment decisions. However, concerns about self-fulfilling prophecy related to withdrawal of life-sustaining therapy (WLST) complicate outcome prediction. This study evaluated the accuracy of guideline-recommended prognostic markers within 14 days after CA for predicting poor 12-month outcomes in patients without WLST during the first four weeks after CA.
methodsThis prospective multicenter observational study enrolled adults who remained comatose 72 h after CA across eight German hospitals between 2014 and 2017. Patients with WLST during the first four weeks, stroke, pre-existing disorders of consciousness, or terminal malignancy were excluded, leaving 101 patients for analysis. Prognostic markers assessed included pupillary light and corneal reflexes (PLR + CR), EEG, somatosensory evoked potentials (SEP), neuron-specific enolase (NSE) concentration, and the best Coma Recovery Scale-Revised (CRS-R) score. Poor outcome was defined as a modified Rankin Scale score of 4-6 at 12 months.
resultsPoor outcomes occurred in 67.3% of patients. Individual markers demonstrated high specificity but limited sensitivity, with variable false-positive rates (FPRs). Repeated assessments and the combination of two or more unfavorable markers markedly reduced FPRs. Within 14 days, the presence of two or more unfavorable markers yielded no false positives and was strongly associated with poor outcome (adjusted OR 34.7). Adding the best CRS-R score to established markers significantly improved prognostic discrimination (AUC 0.925 vs. 0.888).
conclusionsIn patients who remained comatose three days after CA and in whom multimodal prognosis becomes clinically relevant, guideline-recommended assessment identified poor-outcome patients with high specificity and consistency with prior multimodal prognostication cohorts. Although self-fulfilling-prophecy bias cannot be fully excluded in any observational prognostication cohort, the marker profiles of WLST-excluded patients within the first four weeks matched or exceeded those of patients with documented poor outcomes and did not resemble those of recoverable patients, which reduces - though it does not completely rule it out - the likelihood that such bias is the primary reason for the observed associations. The best CRS-R score provided additional prognostic value, particularly in cases of uncertain prognosis, supporting its integration into multimodal assessment frameworks.
trial registrationClinicalTrials.gov: NCT02231060. Registered: August 2014. First patient enrolled: October 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.